CRIS Current Research Information System

RICCI, ANGELA DALIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.793
NA - Nord America 2.346
EU - Europa 1.339
AF - Africa 143
SA - Sud America 140
OC - Oceania 4
Totale 6.765
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.307
SG - Singapore 841
CN - Cina 679
VN - Vietnam 622
IT - Italia 282
SE - Svezia 210
HK - Hong Kong 200
DE - Germania 178
GB - Regno Unito 127
IN - India 102
BR - Brasile 101
KR - Corea 100
IE - Irlanda 96
CH - Svizzera 87
FI - Finlandia 82
NL - Olanda 80
FR - Francia 71
RU - Federazione Russa 57
BD - Bangladesh 52
CI - Costa d'Avorio 44
JP - Giappone 35
SC - Seychelles 32
ID - Indonesia 30
JO - Giordania 24
TG - Togo 22
PH - Filippine 21
CA - Canada 19
AR - Argentina 16
NG - Nigeria 16
AT - Austria 15
TH - Thailandia 15
IQ - Iraq 14
TR - Turchia 13
BG - Bulgaria 12
ZA - Sudafrica 11
MX - Messico 10
ES - Italia 8
PL - Polonia 7
EC - Ecuador 6
PS - Palestinian Territory 6
PY - Paraguay 6
BE - Belgio 5
LT - Lituania 5
MY - Malesia 5
PK - Pakistan 5
UA - Ucraina 5
UZ - Uzbekistan 5
CL - Cile 4
AE - Emirati Arabi Uniti 3
CO - Colombia 3
KE - Kenya 3
MA - Marocco 3
SA - Arabia Saudita 3
TW - Taiwan 3
VE - Venezuela 3
AL - Albania 2
AO - Angola 2
AU - Australia 2
AZ - Azerbaigian 2
CD - Congo 2
CR - Costa Rica 2
DZ - Algeria 2
IL - Israele 2
LB - Libano 2
NP - Nepal 2
NZ - Nuova Zelanda 2
RS - Serbia 2
TT - Trinidad e Tobago 2
AM - Armenia 1
CG - Congo 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
DM - Dominica 1
DO - Repubblica Dominicana 1
EG - Egitto 1
ET - Etiopia 1
GE - Georgia 1
GT - Guatemala 1
HN - Honduras 1
HR - Croazia 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LV - Lettonia 1
LY - Libia 1
MO - Macao, regione amministrativa speciale della Cina 1
MU - Mauritius 1
NI - Nicaragua 1
NO - Norvegia 1
PT - Portogallo 1
RO - Romania 1
SI - Slovenia 1
SV - El Salvador 1
TN - Tunisia 1
UY - Uruguay 1
Totale 6.765
Salva come PNG Salva come JPEG
Città #
Singapore 591
Ashburn 235
San Jose 222
Dallas 210
Hefei 205
Chandler 204
Hong Kong 189
Ho Chi Minh City 169
Hanoi 146
Santa Clara 103
Beijing 101
Boardman 100
Princeton 97
Dublin 94
Seoul 87
Bologna 86
Bern 83
Southend 81
Council Bluffs 78
Fairfield 73
Helsinki 61
New York 56
Los Angeles 51
Lauterbourg 50
Abidjan 44
Houston 33
Redondo Beach 28
Seattle 28
Berlin 25
Florence 25
Haiphong 25
Amman 24
Frankfurt am Main 24
Buffalo 23
Lomé 22
Da Nang 21
São Paulo 20
Tokyo 20
Bengaluru 18
London 17
Redmond 17
Cambridge 16
Jakarta 16
Munich 16
Wilmington 15
Lappeenranta 14
Milan 14
San Diego 14
Woodbridge 14
Rome 13
Turin 13
Shanghai 12
Abeokuta 11
Can Tho 11
Sofia 10
Amsterdam 9
Chicago 9
Orem 9
Bühl 8
Nuremberg 8
Tongling 8
Vienna 8
Washington 8
Boydton 7
Des Moines 7
Guangzhou 7
Hyderabad 7
Hải Dương 7
Ninh Bình 7
San Francisco 7
Stockholm 7
Turku 7
Xi'an 7
Ann Arbor 6
Atlanta 6
Biên Hòa 6
Falkenstein 6
Jinan 6
Mexico City 6
Montreal 6
Olalla 6
Shenzhen 6
Ankara 5
Brussels 5
Cape Town 5
Forlì 5
Groningen 5
Halhul 5
Harbin 5
Istanbul 5
Medford 5
Poplar 5
Quận Bình Thạnh 5
Siena 5
Tianjin 5
Toronto 5
Warsaw 5
Yubileyny 5
Zhengzhou 5
Baghdad 4
Totale 4.255
Salva come PNG Salva come JPEG
Nome #
Specific Toxicity of Maintenance Olaparib Versus Placebo in Advanced Malignancies: A Systematic Review and Meta-analysis 303
Pancreatic mucinous cystadenocarcinoma in a patient harbouring BRCA1 germline mutation effectively treated with olaparib: A case report 234
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumour Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes 229
Percutaneous radiofrequency ablation in intrahepatic cholangiocarcinoma: a retrospective single-center experience 208
Second-line treatment in advanced biliary tract cancer: Today and tomorrow 207
The (Eternal) Debate on Microwave Ablation Versus Radiofrequency Ablation in BCLC-A Hepatocellular Carcinoma 202
How to choose between percutaneous transhepatic and endoscopic biliary drainage in malignant obstructive jaundice: An updated systematic review and meta-analysis 200
Anti-EGFR monoclonal antibodies in advanced biliary tract cancer: A systematic review and meta-analysis 197
The Potential Role of Adjuvant Chemoradiotherapy in Patients with Microscopically Positive (R1) Surgical Margins after Resection of Cholangiocarcinoma 177
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes 169
Bone targeting agents in patients with metastatic prostate cancer: State of the art 165
Hacking pancreatic cancer: Present and future of personalized medicine 162
Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand? 160
Is post-transplant chemotherapy feasible in liver transplantation for colorectal cancer liver metastases? 149
Dose reduction and discontinuation of standard-dose regorafenib associated with adverse drug events in cancer patients: a systematic review and meta-analysis 140
Are FGFR and IDH1-2 alterations a positive prognostic factor in intrahepatic cholangiocarcinoma? An unresolved issue 139
Landscape and future perspectives of immunotherapy in neuroendocrine neoplasia 137
Experimental HER2- targeted therapies for biliary tract cancer 128
Molecular features and targeted therapies in extrahepatic cholangiocarcinoma: Promises and failures 128
Quality of life assessment in renal cell carcinoma Phase II and III clinical trials published between 2010 and 2020: A systematic review 125
Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC risk groups in metastatic renal cell carcinoma: A meta-analysis 124
Tumor-associated macrophages and inflammatory microenvironment in gastric cancer: Novel translational implications 123
The functioning side of the pancreas: a review on insulinomas 121
Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges 111
Novel HER2-directed treatments in advanced gastric carcinoma: Another paradigm shift? 111
Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials 109
Performance and clinical utility of two targeted multigene panels for GIST molecular characterization 108
Assessment of the Risk of Nodal Involvement in Rectal Neuroendocrine Neoplasms: The NOVARA Score, a Multicentre Retrospective Study 104
The Impact of Concomitant Proton Pump Inhibitors on Immunotherapy Efficacy Among Patients with Urothelial Carcinoma: A Meta-Analysis 103
Combining immune checkpoint inhibitors with locoregional therapies in hepatocellular carcinoma 102
Nivolumab: an investigational agent for the treatment of biliary tract cancer 102
Platinum-based adjuvant chemotherapy for upper tract urothelial carcinoma: a change of paradigm? A meta-analysis of aggregate data 101
Combination therapy of dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer 91
Recurrent Uterine Smooth-Muscle Tumors of Uncertain Malignant Potential (STUMP): State of The Art 90
Circulating tumor DNA in biliary tract cancer: Current evidence and future perspectives 89
FGFR inhibitors in elderly patients with advanced biliary tract cancer: an unsolved issue 87
Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials 84
Bayesian Analysis Supports Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma 84
Detecting and targeting NTRK gene fusions in cholangiocarcinoma: news and perspectives 78
Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer 76
Systemic Treatment for Metastatic Biliary Tract Cancer: State of the Art and a Glimpse to the Future 74
IDH inhibitors in advanced cholangiocarcinoma: Another arrow in the quiver? 70
Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives 70
Pd‐l1, tmb, msi, and other predictors of response to immune checkpoint inhibitors in biliary tract cancer 70
The DNA damage repair (DDR) pathway in biliary tract cancer (BTC): A new Pandora's box? 65
Immunotherapy in Biliary Tract Cancer: Worthy of a Second Look 64
Impact of clinicopathological features on immune-based combinations for advanced urothelial carcinoma: A meta-analysis 63
Lenvatinib plus pembrolizumab: the next frontier for the treatment of hepatocellular carcinoma? 59
Atezolizumab in advanced hepatocellular carcinoma: Good things come to those who wait 59
Ivosidenib in IDH-mutant cholangiocarcinoma: where do we stand? 58
First-line immune checkpoint inhibitor-based combinations in unresectable hepatocellular carcinoma: current management and future challenges 58
Precision oncology in cholangiocarcinoma: current issues in clinical trial design and access to targeted therapies 54
Pemigatinib: Hot topics behind the first approval of a targeted therapy in cholangiocarcinoma 53
Recent advances of immunotherapy for biliary tract cancer 52
DNA damage response alterations in gastric cancer: Knocking down a new wall 51
Immune-based combinations for metastatic triple negative breast cancer in clinical trials: current knowledge and therapeutic prospects 50
In Regard to “A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08)” 49
Systemic adjuvant treatment in hepatocellular carcinoma: Tempted to do something rather than nothing 45
Toward personalized therapy for cholangiocarcinoma: new insights and challenges 44
Radiofrequency ablation for intrahepatic cholangiocarcinoma: a tool upon the path of integrative modalities? 44
Treatment-related adverse events of first-line immunotherapy versus sorafenib for advanced hepatocellular carcinoma: a meta-analysis 42
Regarding “HER2 Overexpression as a Poor Prognostic Determinant in Resected Biliary Tract Cancer” 39
Immune-Based Combination Therapies for Advanced Hepatocellular Carcinoma 31
Second-Line Chemotherapy in Elderly Patients with Advanced Biliary Tract Cancer: A Multicenter Real-World Study 29
Molecular Profile and Prognostic Value of BAP1 Mutations in Intrahepatic Cholangiocarcinoma: A Genomic Database Analysis 27
Targeting tumor microenvironment for cholangiocarcinoma: Opportunities for precision medicine 26
Immune-based combinations for advanced hepatocellular carcinoma: Shaping the direction of first-line therapy 22
Totale 6.925
Salva come PNG Salva come JPEG
Categoria #
all - tutte 26.057
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 26.057
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202122 0 0 0 0 0 0 0 0 0 0 0 22
2021/2022596 13 4 8 13 18 5 12 42 168 52 172 89
2022/20231.074 84 115 43 102 77 117 36 62 179 56 77 126
2023/2024309 58 41 20 22 25 50 20 20 6 27 11 9
2024/20251.284 61 190 151 102 142 61 76 44 13 93 99 252
2025/20263.509 321 389 469 229 311 140 323 168 630 273 147 109
Totale 6.925